International Stem Cell Corp. (ISCO) Expands Protection of Proprietary Technology with Key Patent for Liver Disease Program
Today before the opening bell, International Stem Cell Corporation announced that the United States Patent and Trademark Office (USPTO) awarded the company with a patent for a method of creating pure populations of definitive endoderm, precursor cells to liver and pancreas cells, from human pluripotent stem cells. Allowing the production of necessary quantities of precursor cells in a more efficient and cost effective manner, this new patent is a key part of ISCO's metabolic liver disease program. The patent, 8,268,621, adds to the company's growing intellectual property portfolio relating to the development of potential treatments for diseases without cure using…